OmniAb, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Matthew W. Foehr
- Full Time Employees
- 114
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5980 Horton Street EmeryVille CA United States of America 94608
- IPO Date
- Sep 30, 2021
- CIK
- 0001846253
- Website
- omniab.com
- Similar Companies
- Business
- OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Company News
OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
OmniAb to Participate in Two Investor Conferences in March
Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates
OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
OmniAb to Participate in the Jefferies Global Healthcare Conference
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit
OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights
OmniAb to Participate in Five Investor Conferences in May
OmniAb to Report First Quarter 2024 Financial Results on May 9
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript